Literature DB >> 8602817

Surgical resection of pulmonary metastases from nasopharyngeal carcinoma.

L C Cheng1, J S Sham, C S Chiu, K H Fu, J W Lee, C K Mok.   

Abstract

BACKGROUND: Nasopharyngeal carcinoma (NPC), unlike other head and neck cancers,is known for its propensity for distant metastases. Chemotherapy remains the mainstay of treatment because of this and the chemosensitivity of the tumour, but long-term control is rare. The surgical management of pulmonary metastases of other extrathoracic malignancies prompted this review of surgical management of patients with NPC.
METHODS: Thirteen thoracotomies were performed in 12 patients with pulmonary metastases as the first and only site of relapse of nasopharyngeal carcinoma. Postoperative chemotherapy was given in four patients, radiotherapy to the mediastinum in one patient and both chemotherapy and radiotherapy in two patients. The survival pattern of this group of 12 patients was compared with a historical control group consisting of 65 patients without surgical resection.
RESULTS: Lymph node involvement was documented in four patients during operation. Four patients relapsed after surgical resection, two of them were from the group of three patients with lymph node involvement. The site of subsequent relapse was the lung for three patients and the skeletal system for the fourth. The 2 year actuarial survival of the surgically resected group compared favourably with the historical control group (80% and 24.1%, respectively; P=0.0002 by Mantel-Cox text).
CONCLUSIONS: Surgical resection of pulmonary metastases from NPC seems to be a promising approach thought the effect of case selection cannot be excluded and further studies are indicated. The importance of exploration and dissection of mediastinal nodes in the surgical management of pulmonary metastases from NPC was demonstrated.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8602817     DOI: 10.1111/j.1445-2197.1996.tb01114.x

Source DB:  PubMed          Journal:  Aust N Z J Surg        ISSN: 0004-8682


  6 in total

1.  Efficacy of local therapy to metastatic foci in nasopharyngeal carcinoma: large-cohort strictly-matched retrospective study.

Authors:  Meng-Xia Zhang; Ting Liu; Rui You; Xiong Zou; Yong-Long Liu; Xi Ding; Chong-Yang Duan; Han-Shi Xu; You-Ping Liu; Rou Jiang; Zhi-Qiang Wang; Chao Lin; Yu-Long Xie; Si-Yuan Chen; Yan-Feng Ouyang; Ruo-Qi Xie; Yi-Jun Hua; Rui Sun; Pei-Yu Huang; Shun-Lan Wang; Ming-Yuan Chen
Journal:  Ther Adv Med Oncol       Date:  2022-07-15       Impact factor: 5.485

Review 2.  Optimal management of oligometastatic nasopharyngeal carcinoma.

Authors:  Honggen Liu; Peiying Yang; Yingjie Jia
Journal:  Eur Arch Otorhinolaryngol       Date:  2021-06-05       Impact factor: 2.503

3.  Factors determining the survival of nasopharyngeal carcinoma with lung metastasis alone: does combined modality treatment benefit?

Authors:  Xun Cao; Li-Ru He; Fang-Yun Xie; You-Fang Chen; Zhe-Sheng Wen
Journal:  BMC Cancer       Date:  2011-08-24       Impact factor: 4.430

4.  Prognosticators and risk grouping in patients with lung metastasis from nasopharyngeal carcinoma: a more accurate and appropriate assessment of prognosis.

Authors:  Xun Cao; Rong-Zhen Luo; Li-Ru He; Yong Li; Wen-Qian Lin; You-Fang Chen; Zhe-Sheng Wen
Journal:  Radiat Oncol       Date:  2011-08-26       Impact factor: 3.481

5.  Locoregional radiotherapy in patients with distant metastases of nasopharyngeal carcinoma at diagnosis.

Authors:  Ming-Yuan Chen; Rou Jiang; Ling Guo; Xiong Zou; Qing Liu; Rui Sun; Fang Qiu; Zhong-Jun Xia; Hui-Qiang Huang; Li Zhang; Ming-Huang Hong; Hai-Qiang Mai; Chao-Nan Qian
Journal:  Chin J Cancer       Date:  2013-11

6.  Oral Maintenance Chemotherapy Using S-1/Capecitabine in Metastatic Nasopharyngeal Carcinoma Patients After Systemic Chemotherapy: A Single-Institution Experience.

Authors:  Qiaojuan Guo; Mengwei Chen; Hanchuan Xu; Tianzhu Lu; Han Zhou; Yanyan Chen; Jingfeng Zong; Yun Xu; Bijuan Chen; Bingyi Wang; Lili Zhu; Jianji Pan; Shaojun Lin
Journal:  Cancer Manag Res       Date:  2020-02-25       Impact factor: 3.989

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.